|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.5 TWD | -1.32% |
|
-6.73% | -27.40% |
Great Novel Therapeutics Biotech & Medicals reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was TWD 4.76 million compared to TWD 0.54 million a year ago. Net loss was TWD 34.05 million compared to TWD 28.65 million a year ago.
Basic loss per share from continuing operations was TWD 0.99 compared to TWD 1.27 a year ago. Diluted loss per share from continuing operations was TWD 0.99 compared to TWD 1.27 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -27.40% | 57.92M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS 
